Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration
Key facts
- Study ID
- NCT03376841
- Run by
- Allergan
- People needed
- 16
- Starts
- 2017-06-06
- Expected to finish
- 2017-12-17
- Last updated by the study team
- 2018-01-11
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.